CSL Limited Breaks Ground on $1.5 Billion Illinois Plant as Turnaround Pressure Builds
CSL Limited has begun a $1.5 billion expansion of its Kankakee, Illinois, manufacturing site, aiming to add at least 300 jobs and boost plasma-derived therapy output by 2031. The move follows an 81% drop in first-half profit and recent leadership changes. CSL also repurchased 62,472 shares for about A$9.1 million on March 10. Shares closed at A$144.56 Tuesday, up 1.65% but near a 52-week low.